Search

AB Science SA

Open

1.406 2.33

Overview

Share price change

24h

Current

Min

1.358

Max

1.436

Key metrics

By Trading Economics

Income

-5.2M

Sales

515K

Profit margin

-1,005.243

Employees

36

EBITDA

-2.5M

Market Stats

By TradingEconomics

Market Cap

94M

Previous open

-0.92

Previous close

1.406

Technical Score

By Trading Central

Confidence

Bearish Evidence

AB Science SA Chart

Past performance is not a reliable indicator of future results.

Related News

6 Jan 2026, 21:14 UTC

Major Market Movers

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6 Jan 2026, 19:23 UTC

Acquisitions, Mergers, Takeovers

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6 Jan 2026, 17:41 UTC

Major Market Movers

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6 Jan 2026, 15:46 UTC

Acquisitions, Mergers, Takeovers

Advent International Leads InPost Takeover Offer, Sky News Says

6 Jan 2026, 15:37 UTC

Major Market Movers

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6 Jan 2026, 23:46 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

6 Jan 2026, 23:35 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6 Jan 2026, 23:19 UTC

Market Talk

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6 Jan 2026, 22:53 UTC

Market Talk

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6 Jan 2026, 22:03 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6 Jan 2026, 22:03 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Jan 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 Jan 2026, 21:12 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 Jan 2026, 21:12 UTC

Market Talk

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6 Jan 2026, 20:59 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6 Jan 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6 Jan 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6 Jan 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced Imminently, Sources Say -- WSJ

6 Jan 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6 Jan 2026, 20:01 UTC

Market Talk

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6 Jan 2026, 19:52 UTC

Market Talk

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6 Jan 2026, 19:46 UTC

Acquisitions, Mergers, Takeovers

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6 Jan 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

OneStream to Go Private Through $6.4B Hg Acquisition

6 Jan 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6 Jan 2026, 17:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

6 Jan 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

6 Jan 2026, 15:57 UTC

Market Talk

Crude Futures Ease Back From Early Gains -- Market Talk

6 Jan 2026, 15:34 UTC

Market Talk
Earnings

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6 Jan 2026, 15:27 UTC

Market Talk

German Inflation Won't Fall Much Further in 2026 -- Market Talk

AB Science SA Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.426 / 1.448Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
help-icon Live chat